尿酸转运体、ADH1B、GCKR和MEPE基因变异与无症状高尿酸血症向痛风转变相关:英国生物银行高加索人群首个痛风与无症状高尿酸血症GWAS结果
基于英国生物银行高加索人群的痛风与无症状高尿酸血症(AH)对照的GWAS研究,发现13个独立SNP(位于ABCG2、SLC2A9、SLC22A11、GCKR、MEPE、PPM1K-DT、LOC105377323和ADH1B)与AH向痛风转变相关,其中12个为新发现,ADH1B的rs1229984首次被鉴定为痛风GWAS位点。最佳多基因风险评分(PRS)模型基于17个SNP,预测能力为58.5%,加入人口学因素后升至69.2%。
要点
- 13个独立SNP与无症状高尿酸血症向痛风转变相关,其中12个为新发现。
- ADH1B的rs1229984首次被鉴定为痛风GWAS位点。
- 基于17个SNP的PRS预测AH向痛风转变能力为58.5%,加入人口学因素后达69.2%。
核心结论
- 尿酸转运体基因与痛风的关联支持高尿酸血症在痛风发病中的核心作用。
- 需要更大规模的GWAS来确定炎症通路变异是否参与从无症状高尿酸血症到痛风的进展。
研究设计与样本
- 进行GWAS,以发现队列的汇总统计量为基础数据集、复制队列为目标数据集生成多基因风险评分(PRS),并评估模型预测能力。
- 还分别以血清尿酸<6.0 mg/dL和<7.0 mg/dL为阈值,进行痛风与正常尿酸对照的GWAS。
主要发现
- 13个独立SNP(位于ABCG2、SLC2A9、SLC22A11、GCKR、MEPE、PPM1K-DT、LOC105377323和ADH1B)达到全基因组显著性并重复验证为无症状高尿酸血症向痛风转变的预测因子。
- 13个关联中的12个为该转变的新发现,rs1229984(ADH1B)首次被鉴定为痛风GWAS位点。
- 最佳PRS模型基于17个SNP的关联数据生成,预测能力为58.5%,加入人口学因素后增至69.2%。
- 两个新SNP rs760077(MTX1)和rs3800307(PRSS16)在两种血清尿酸阈值下与痛风(对比正常尿酸对照)的关联均达到GWAS显著性。
关键数值与推荐
- 无症状高尿酸血症对照定义为血清尿酸≥6.0 mg/dL。
- 正常尿酸对照分别采用血清尿酸<6.0 mg/dL和<7.0 mg/dL阈值。
- PRS预测能力:基于17个SNP为58.5%,加入人口学因素后为69.2%。
临床怎么用
- 基于17个SNP的PRS模型可用于评估无症状高尿酸血症患者向痛风转变的风险,加入人口学因素可提高预测能力。
- ADH1B、ABCG2、SLC2A9等基因变异可作为痛风风险分层和发病机制研究的候选标志物。
局限性
- 需要更大规模的GWAS来确定炎症通路变异是否参与从无症状高尿酸血症到痛风的进展。
- 研究仅基于英国生物银行高加索人群,结果外推至其他人群需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To perform a genome-wide association study (GWAS) of gout cases versus asymptomatic hyperuricaemia (AH) controls, and gout cases versus normouricaemia controls, and to generate a polygenic risk score (PRS) to determine gout-case versus AH-control status. METHODS: Gout cases and AH controls (serum urate (SU) ≥6.0 mg/dL) from the UK Biobank were divided into discovery (4934 cases, 56 948 controls) and replication (2115 cases, 24 406 controls) cohorts. GWAS was conducted and PRS generated using summary statistics in discovery cohort as the base dataset and the replication cohort as the target dataset. The predictive ability of the model was evaluated. GWAS were performed to identify variants associated with gout compared with normouricaemic controls using SU <6.0 mg/dL and <7.0 mg/dL thresholds, respectively. RESULTS: Thirteen independent single nucleotide polymorphisms (SNPs) in ABCG2, SLC2A9, SLC22A11, GCKR, MEPE, PPM1K-DT, LOC105377323 and ADH1B reached genome-wide significance and replicated as predictors of AH to gout transition. Twelve of 13 associations were novel for this transition, and rs1229984 (ADH1B) was identified as GWAS locus for gout for the first time. The best PRS model was generated from association data of 17 SNPs; and had predictive ability of 58.5% that increased to 69.2% on including demographic factors. Two novel SNPs rs760077(MTX1) and rs3800307(PRSS16) achieved GWAS significance for association with gout compared with normouricaemic controls using both SU thresholds. CONCLUSION: The association of urate transporters with gout supports the central role of hyperuricaemia in its pathogenesis. Larger GWAS are required to identify if variants in inflammatory pathways contribute to progression from AH to gout.
引用
- Sandoval-Plata G, Morgan K, Abhishek A, et al. Variants in urate transporters, ADH1B, GCKR and MEPE genes associate with transition from asymptomatic hyperuricaemia to gout: results of the first gout versus asymptomatic hyperuricaemia GWAS in Caucasians using data from the UK Biobank. Ann Rheum Dis. 2021. PMID: 33832965. doi:10.1136/annrheumdis-2020-219796
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。